2004]. Table 1. Glutamatergic drugs currently in development

for the treatment of schizophrenia. Metabotropic glutamatergic receptors: Allosteric potentiators There has been some interest in developing allosteric potentiators of metabotropic glutamate receptors [Johnson et al. 2004], and two pharmaceutical companies have published data on these compounds (see Table 1). There are several theoretical advantages of allosteric potentiation in PCI-24781 price targeting the glutamatergic system. As endogenous ligand is required for their action, they should have a lower propensity to side effects; they may also be less prone to desensitization which occurs Inhibitors,research,lifescience,medical with drugs targeting the active site. LY379268 is an allosteric drug

potentiating glutamate signalling at the mGlu2 receptor currently in development by Lilly. It has been shown to block ketamine-induced glutamate release, as well as ketamine-induced dopamine and histamine release in the prefrontal cortex, and norepinephrine release in hippocampus [Fell et al. 2010; Lorrain et al. Inhibitors,research,lifescience,medical 2003a, 2003b]. It has also been shown to inhibit MK-801-induced retrosplenial cortex damage when injected into thalamus or cortex [Carter et al. 2004], suggesting that it may be neuroprotective in the early Inhibitors,research,lifescience,medical stages of psychosis. 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is an allosteric potentiator of the mGlu5 receptor developed by Merck [Lindsley et al. 2004]. It increases Inhibitors,research,lifescience,medical the affinity of glutamate for the receptor, leading to an enhancement of NMDA receptor activity (Figure 6). It has been shown to attenuate amphetamine-induced PPI deficits [Kinney et al. 2005], and to reverse MK-801-induced elevation in pyramidal cell activity [Lecourtier

et al. 2007]. It was also effective in an animal model of negative symptoms (MK-801-induced impairment of sucrose preference) [Vardigan et Inhibitors,research,lifescience,medical al. 2010], and showed superior efficacy compared with mGlu2/3 agonists in reversing MK-801-induced cognitive impairment [Vales et al. 2010; Stefani and Moghaddam, 2010]. CDPPB was found to have a U-shaped dose—response curve on cognitive function and on GluR1 phosphorylation, however, suggesting a fairly tight therapeutic window [Uslaner et al. 2009]. Glutamate and illness progression in schizophrenia: A critical Sitaxentan window of opportunity? Elevated cortical glutamate activity in schizophrenia appears to be most marked in the early phases of the illness [Théberge et al. 2002] and in the prodrome [Stone et al. 2009]. Thus, it makes intuitive sense that drugs targeting excess glutamate release may be of most benefit when given during these stages. Indeed, as the illness progresses, it appears that, rather than being overactive, that cortical glutamate system may be reduced in function compared with healthy volunteers [Théberge et al. 2003].